Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajiv Loungani

Psychiatry Jacksonville, FL Medical Doctor

NPI 1447516802 CMS profile 1471214

2320 3Rd St S Ste 13, Jacksonville, FL 32250

Open in the dashboard

General payments

$6,219

272 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajiv Loungani of Jacksonville, FL is reported in the CMS Open Payments database as having received $6,219 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $866 30
2024 General $781 33
2023 General $726 31
2022 General $1,081 58
2021 General $2,146 96
2020 General $506 23
2019 General $113 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajiv Loungani
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Rajiv Loungani were reported at $866. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Rajiv Loungani Psychiatry median Middle half National median
2019 $113 $184 $59–$605 $163
2020 $506 $119 $36–$372 $114
2021 $2,146 $143 $43–$576 $132
2022 $1,081 $153 $50–$590 $149
2023 $726 $170 $56–$651 $160
2024 $781 $179 $57–$673 $164
2025 $866 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $1,248 53 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,119 46 payments
  3. Bausch Health US, LLC $1,118 65 payments
  4. Supernus Pharmaceuticals, Inc. $723 30 payments
  5. AbbVie, Inc. $593 26 payments
  6. Janssen Pharmaceuticals, Inc $277 7 payments
  7. Axsome Therapeutics, Inc. $227 8 payments
  8. Lundbeck LLC $209 10 payments
  9. Allergan Inc. $197 10 payments
  10. Avanir Pharmaceuticals, Inc. $113 1 payment
  11. Other $396 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,093 264 payments
  2. Education $126 8 payments
Products named General payments · program years 2019–2025
  1. APLENZIN $1,143 66 payments
  2. TRINTELLIX $1,095 45 payments
  3. CAPLYTA $1,088 48 payments
  4. WELLBUTRIN $745 42 payments
  5. VRAYLAR Neuroscience $558 25 payments
  6. QELBREE Psychology $421 21 payments
  7. Qelbree Viloxazine Hydrochloride $302 9 payments
  8. VRAYLAR Neuroscience $232 11 payments
  9. Auvelity $227 8 payments
  10. SPRAVATO $220 4 payments
  11. Other $1,707 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

255

Median for Psychiatry & Neurology: 100

Drug cost

$21,419

Median for Psychiatry & Neurology: $2,986

Branded share of claims

13.3%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $17,029
Lurasidone Hcl Generic 11 $1,996
Clonazepam Generic 52 $449
Quetiapine Fumarate Generic 20 $370
Gabapentin Generic 12 $336
Duloxetine Hcl Generic 12 $258
Bupropion Xl Bupropion Hcl Brand 22 $203
Eszopiclone Generic 12 $190
Propranolol Hcl Generic 15 $165
Diazepam Generic 19 $140

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $316
$316 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $161
$161 — —
APLENZIN
  • Bausch Health US, LLC $103
$103 — —
WELLBUTRIN
  • Bausch Health US, LLC $102
$102 — —
Secuado
  • Noven Therapeutics, LLC $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record